Osteosarcoma is one of the most malignant tumors of childhood and adolescence that is often resistant to standard chemo- and radio-therapy. Geldanamycin and geldanamycin analogs have been recently studied as potential anticancer agents for osteosarcoma treatment. Here, for the first time, we have presented novel anticancer mechanisms of geldanamycin biological activity. Moreover, we demonstrated an association between the effects of geldanamycin on the major heat shock proteins (HSPs) and the overall survival of highly metastatic human osteosarcoma 143B cells. We demonstrated that the treatment of 143B cells with geldanamycin caused a subsequent upregulation of cytoplasmic Hsp90 and Hsp70 whose activity is at least partly responsible for cancer development and drug resistance. On the other hand, geldanamycin induced upregulation of Hsp60 gene expression, and a simultaneous loss of hyperacetylated Hsp60 mitochondrial protein pool resulting in decreased viability and augmented cancer cell death. Hyperacetylation of Hsp60 seems to be associated with anticancer activity of geldanamycin. In light of the fact that mitochondrial dysfunction plays a critical role in the apoptotic signaling pathway, the presented data may support a hypothesis that Hsp60 can be another functional part of mitochondria-related acetylome being a potential target for developing novel anticancer strategies.
References
[1]
Broadhead ML, Clark JCM, Myers DE, Dass CR, Choong PFM (2011) The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011: 959248–959248.
[2]
Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clinical advances in hematology & oncology: H&O 8: 705–718.
[3]
Chou AJ, Geller DS, Gorlick R (2008) Therapy for osteosarcoma: where do we go from here? Paediatric drugs 10: 315–327.
[4]
Gill J, Ahluwalia MK, Geller D, Gorlick R (2013) New targets and approaches in osteosarcoma. Pharmacology & therapeutics 137: 89–99.
[5]
Khalil AA, Kabapy NF, Deraz SF, Smith C (2011) Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets? Biochimica Et Biophysica Acta-Reviews on Cancer 1816: 89–104.
[6]
Macario AJL, Cappello F, Zummo G, de Macario EC (2010) Chaperonopathies of senescence and the scrambling of interactions between the chaperoning and the immune systems. Aging, Cancer, and Age-Related Diseases: Common Mechanism? 1197: 85–93.
[7]
Rappa F, Farina F, Zummo G, David S, Campanella C, et al. (2012) HSP-Molecular Chaperones in Cancer Biogenesis and Tumor Therapy: An Overview. Anticancer Research 32: 5139–5150.
[8]
Neckers L, Workman P (2012) Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? Clinical Cancer Research 18: 64–76.
[9]
Kaul Z, Yaguchi T, Kaul SC, Wadhwa R (2006) Quantum Dot-Based Protein Imaging and Functional Significance of Two Mitochondrial Chaperones in Cellular Senescence and Carcinogenesis. Understanding and Modulating Aging 1067: 469–473.
[10]
Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR (1998) Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. International Journal of Cancer 79: 468–475.
[11]
Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, et al. (2000) Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathology Research and Practice 196: 665–673.
[12]
Almeida MB, Martins do Nascimento JL, Herculano AM, Crespo-Lopez ME (2011) Molecular chaperones: Toward new therapeutic tools. Biomedicine & Pharmacotherapy 65: 239–243.
[13]
Chang YS, Lo CW, Sun FC, Chang MDT, Lai YK (2006) Differential expression of Hsp90 isoforms in geldanamycin-treated 9L cells. Biochemical and Biophysical Research Communications 344: 37–44.
[14]
Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G (1998) The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review. Pharmacology & Therapeutics 79: 129–168.
[15]
Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, et al. (2010) A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemotherapy and Pharmacology 66: 535–545.
[16]
Cappello F, David S, Rappa F, Bucchieri F, Marasa L, et al. (2005) The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. Bmc Cancer 5.
[17]
Cappello F, de Macario EC, Marasa L, Zummo G, Macario AJL (2008) Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biology & Therapy 7: 801–809.
[18]
Powers MV, Workman P (2007) Inhibitors of the heat shock response: Biology and pharmacology. Febs Letters 581: 3758–3769.
[19]
Kim HR, Kang HS, Kim HD (1999) Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. Iubmb Life 48: 429–433.
[20]
Lai MT, Huang KL, Chang WM, Lai YK (2003) Geldanamycin induction of grp78 requires activation of reactive oxygen species via ER stress responsive elements in 9L rat brain tumour cells. Cellular Signalling 15: 585–595.
[21]
Chao C-C, Sun F-C, Wang C-H, Lo C-W, Chang Y-S, et al. (2008) Concerted actions of multiple transcription elements confer differential Transactivation of HSP90 isoforms in geldanamycin-treated 9L rat gliosarcoma cells. Journal of Cellular Biochemistry 104: 1286–1296.
[22]
Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, et al. (2012) Geldanamycin and its derivatives as Hsp90 inhibitors. Frontiers in Bioscience-Landmark 17: 2269–2277.
[23]
Xie Q, Wondergem R, Shen Y, Cavey G, Ke J, et al. (2011) Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proceedings of the National Academy of Sciences of the United States of America 108: 4105–4110.
[24]
Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacological evaluation of geldanamycin as an antitumor agent. Cancer Chemotherapy and Pharmacology 36: 305–315.
[25]
Campanella C, Bucchieri F, Ardizzone NM, Gammazza AM, Montalbano A, et al. (2008) Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. European Journal of Histochemistry 52: 221–228.
[26]
Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, et al. (2005) Abrogation of heat shock protein 70 induction as a strategy, to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Research 65: 10536–10544.
[27]
McCollum AK, TenEyck CJ, Sauer BM, Toft DO, Erlichman C (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Research 66: 10967–10975.
[28]
McCollum AK, Lukasiewicz KB, TenEyck CJ, Lingle WL, Toft DO, et al. (2008) Cisplatin abrogates the geldanamycin-induced heat shock response. Molecular Cancer Therapeutics 7: 3256–3264.
[29]
Singh B, Patel HV, Ridley RG, Freeman KB, Gupta RS (1990) Mitochondrial import of the human chaperonin (HSP60) protein. Biochemical and Biophysical Research Communications 169: 391–396.
[30]
Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN (2012) HDAC inhibitors and chaperone function. Advances in cancer research 116: 239–262.
[31]
Nahleh Z, Tfayli A, Nijim A, El Sayed A, Nahle Z (2012) Heat shock proteins in cancer: targeting the ‘chaperones’ (vol 4, pg 927, 2012). Future Medicinal Chemistry 4: 1766–1766.
[32]
Bertram J, Palfner K, Hiddemann W, Kneba M (1996) Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta. Anti-Cancer Drugs 7: 838–845.
[33]
Yufu Y, Nishimura J, Nawata H (1992) High constitutive expression ofheat shock protein 90-alpha in human acute-leukemia cells. Leukemia Research 16: 597–605.
[34]
Sittler A, Lurz R, Lueder G, Priller J, Hayer-Hartl MK, et al. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Human Molecular Genetics 10: 1307–1315.
[35]
Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE (2013) Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell International 13.
[36]
Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, et al. (2006) Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death and Differentiation 13: 1434–1441.
[37]
Cappello F, Zummo G (2005) HSP60 expression during carcinogenesis: a molecular “Proteus” of carcinogenesis? Cell Stress & Chaperones 10: 263–264.
[38]
Karbowski M, Spodnik JH, Teranishi M, Wozniak M, Nishizawa Y, et al. (2001) Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. Journal of Cell Science 114: 281–291.
[39]
Sol EM, Wagner SA, Weinert BT, Kumar A, Kim H-S, et al. (2012) Proteomic Investigations of Lysine Acetylation Identify Diverse Substrates of Mitochondrial Deacetylase Sirt3. Plos One 7.
[40]
Finley LWS, Haigis MC (2012) Metabolic regulation by SIRT3: implications for tumorigenesis. Trends in Molecular Medicine 18: 516–523.
[41]
Lombard DB, Alt FW, Cheng H-L, Bunkenborg J, Streeper RS, et al. (2007) Mammalian sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Molecular and Cellular Biology 27: 8807–8814.
[42]
Lu Z, Bourdi M, Li JH, Aponte AM, Chen Y, et al. (2011) Sirt3-dependent deacetylation exacerbates acetaminophen hepatotoxicity. Embo Reports 8: 841–846.
[43]
Neuwelt A, Wu J, Knap N, Losin M, Neuwelt E, et al. (2009) Using Acetaminophen's Toxicity Mechanism to Enhance Cisplatin Efficacy in Hepatocarcinoma and Hepatoblastoma Cell Lines. Neoplasia 11: 1003–1011.
